AIDS Malignancy Consortium (AMC)

艾滋病恶性肿瘤协会 (AMC)

• 批准号: 9788273
• 负责人: RONALD T. MITSUYASU
• 金额: $ 1745.15万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9788273
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; Accountability; Acquired Immunodeficiency Syndrome; Address; Adolescent; Africa South of the Sahara; African; Anal Intraepithelial Neoplasia; Anus; Area; Behavioral; Behavioral Sciences; Biological Markers; Biology; Cancer Biology; Clinical; Clinical Data; Clinical Trials; Clinical Trials Cooperative Group; Communities; Conduct Clinical Trials; Decision Making; Disease; Dose; Drug Kinetics; Education; Enrollment; Epidemic; Evaluation; Genetic screening method; Grant; HIV; Hematology; Human Papillomavirus; Immunologics; Incidence; Individual; International; International Aspects; Intervention; Kaposi Sarcoma; Laboratories; Laboratory Study; Leadership; Logistics; Lymphoma; Malignant Neoplasms; Malignant neoplasm of anus; Memorial Sloan-Kettering Cancer Center; Mission; Morbidity - disease rate; National Cancer Institute; National Institute of Allergy and Infectious Disease; Non-Hodgkin' s Lymphoma; Pathologic; Patients; Pharmaceutical Preparations; Pharmacology; Population; Prevention; Protocols documentation; Publishing; Randomized Controlled Trials; Research; Research Personnel; Resources; Role; Sampling; Site; Squamous intraepithelial lesion; Strategic Planning; Structure; Supervision; Surveys; Time; Translational Research; United States National Institutes of Health; Work; antiretroviral therapy; authority; cancer clinical trial; cancer prevention; cancer specimen resource; cohesion; data management; improved; mortality; oncology; operation; outreach; prevent; protocol development; public health relevance; research clinical testing; screening; standard of care; statistical center; targeted cancer therapy; tumor; virology; working group

 DESCRIPTION (provided by applicant): The AIDS Malignancy Consortium (AMC) was established in 1995 and has been at the forefront of the clinical evaluation of interventions for the treatment and prevention of malignancies in HIV and in studying the biology of cancers in HIV in the context of its clinical trials. Since that time the AMC has conducted 96 clinical trials surveys and laboratory studies involving 3484 patients with HIV-associated cancers and published on a wide variety of topics in AIDS malignancies. Several key scientific findings that emerged from AMC studies have led to improvements in the treatment or management of patients and have helped establish the current standard of care for several of these tumors, including Kaposi's sarcoma, non-Hodgkin's lymphoma, anal cancer and anal intraepithelial neoplasia. In addition, the AMC is a leader in the pharmacokinetic assessment of new targeted cancer therapies in conjunction with antiretroviral therapy, which has helped define safe doses of these drugs when used in combination. The AMC is also conducting clinical trials in HIV-associated cancers in sub-Saharan Africa where the epidemic of HIV and cancer has grown substantially. The participation of many of the key clinical and laboratory researchers in AIDS malignancies in the USA has made the AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. We propose to continue and expand our domestic and international clinical trials work in these areas, including the ANCHOR trial, a large randomized controlled study investigating the role of routine anal screening and intervention for high-grade anal squamous intraepithelial lesions for the prevention of anal cancer in HIV, which has rapidly increased in incidence recently.

 描述（由适用提供）：艾滋病恶性财团（AMC）于1995年成立，一直处于对HIV治疗和预防HIV治疗和预防HIV的治疗和预防的临床评估以及研究临床试验背景下HIV的癌症生物学的最前沿。自那时以来，AMC进行了96次临床试验调查和实验室研究，涉及3484例与HIV相关的癌症患者，并发表了有关艾滋病恶性肿瘤的各种主题。从AMC研究中出现的几个关键科学发现导致了患者治疗或管理的改善，并帮助建立了当前的其中几种肿瘤的护理标准，包括Kaposi的肉瘤，非霍奇金的淋巴瘤，肛门癌，肛门癌和上皮内肿瘤。此外，AMC是对新靶向癌症疗法的药代动力学评估的领导者，并结合了抗逆转录病毒疗法，该疗法有助于将这些药物的安全剂量结合起来。 AMC还在撒哈拉以南非洲的艾滋病毒相关癌症中进行临床试验，艾滋病毒和癌症的流行已经大大增加。许多关键的临床和实验室研究人员参与美国的艾滋病恶性肿瘤，使AMC成为全球主要的临床试验小组，致力于改善该人群中癌症的治疗和预防。我们建议在这些领域继续进行并扩大我们的国内和国际临床试验工作，包括锚定试验，这是一项大量的随机对照研究，研究了常规肛门筛查和干预措施对高级肛门鳞状上皮内病变的作用，以预防HIV中的肛门癌，最近发病率迅速增加。

项目成果

Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.

• DOI: 10.1097/cco.0b013e328363dfee
• 发表时间: 2013-09
• 期刊: Current opinion in oncology
• 影响因子: 3.4
• 作者: Gantt S;Casper C;Ambinder RF
• 通讯作者: Ambinder RF

AIDS-associated Kaposi's sarcoma: Is there still a role for interferon alfa?

• DOI: 10.1016/j.cytogfr.2007.06.005
• 发表时间: 2007-10-01
• 期刊: CYTOKINE & GROWTH FACTOR REVIEWS
• 影响因子: 13
• 作者: Krown, Susan E.

HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

• DOI: 10.1086/592298
• 发表时间: 2008-11-01
• 期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• 作者: Sullivan RJ;Pantanowitz L;Casper C;Stebbing J;Dezube BJ
• 通讯作者: Dezube BJ

How do viruses trick B cells into becoming lymphomas?

• DOI: 10.1097/moh.0000000000000060
• 发表时间: 2014-07
• 期刊: Current opinion in hematology
• 影响因子: 3.2
• 作者: Cesarman E

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

• DOI: 10.1002/cncr.28554
• 发表时间: 2014-04-15
• 期刊: CANCER
• 影响因子: 6.2
• 作者: Rudek, Michelle A.;Moore, Page C.;Mitsuyasu, Ronald T.;Dezube, Bruce J.;Aboulafia, David;Gerecitano, John;Sullivan, Ryan;Cianfrocca, Mary E.;Henry, David H.;Ratner, Lee;Haigentz, Missak, Jr.;Dowlati, Afshin;Little, Richard F.;Ivy, Susan Percy;Deeken, John F.
• 通讯作者: Deeken, John F.